UCSF nephrologist Flavio Vincenti, MD, is the lead author of a paper in the March 2010 issue of the American Journal of Transplantation that reports results from a Phase III clinical trial for a new drug that selectively blocks immune suppression for kidney transplants. The drug, belatacept, is given to kidney-transplant recipients to prevent the immune system from rejecting the new organ. Vincenti and his co-investigators found that belatacept may be as effective as the commonly used anti-rejection drug cyclosporine, but with fewer side effects and superior kidney function after 12 months.
February 19, 2010
February 11, 2010
Researchers, who are interested in taking their research from the bench to the bedside, are encouraged to apply for a catalyst award by March 1.
February 03, 2010
UCSF Chancellor Susan Desmond-Hellmann outlines a vision for faster development of better, cheaper drugs to fight cancer.
January 25, 2010
Some of the leading scientists in bioengineering, nanotechnology and pharmaco-genomics will gather on Tuesday, January 26, 2010 to discuss how to harness the tools of these emerging fields to develop new diagnostics and treatments for complex diseases.
December 15, 2009
A UCSF researcher takes a novel approach to understanding how indigenous healers diagnose and treat disease, and finds many similarities to Western medical concepts.